Physician profile
Clay Agee
NPI 1194201277
$4,302.69
in general payments reported to CMS, 2019-2025
26 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $267 · 2023: $780 · 2024: $1,220 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.60 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $888.86 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $749.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $360.72 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $240.80 | 2022-2025 | Omnipod |
| Abbott Laboratories | $236.03 | 2022-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $207.65 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $180.44 | 2023-2025 | Korlym |
| Amgen INC. | $178.70 | 2023-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $173.73 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $166.50 | 2022-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $142.56 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $124.42 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $98.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $80.82 | 2023-2025 | |
| Abbvie INC. | $75.82 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $70.61 | 2025 | |
| Chiesi USA, INC. | $69.75 | 2024-2025 | Mycapssa |
| Glaxosmithkline, LLC. | $55.36 | 2025 | Shingrix, Arexvy |
| Sequel Med Tech, LLC | $37.86 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.79 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $32.03 | 2023-2024 | Veozah |
| Ascendis Pharma Endocrinology INC | $27.15 | 2023 | |
| Alexion Pharmaceuticals, INC. | $22.20 | 2024 | Strensiq |
| Recordati_rare_diseases_inc. | $17.01 | 2024 | Isturisa, Signifor Lar |
| Averitas Pharma INC. | $16.72 | 2025 | Qutenza |
| Exact Sciences Corporation | $13.37 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Agee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.